Hamilton James C., chief medical officer at Arrowhead Pharmaceuticals, reported the sale of 10,000 shares of common stock on March 5, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged 10b5-1 trading plan.
The shares were sold at a weighted average price of $64.19, producing a gross transaction value of $641,900. Reported sale prices ranged from $63.80 to $64.51. Following the disposition, Hamilton James C. directly holds 236,958 shares of Arrowhead Pharmaceuticals, Inc.
At the time of the filing, Arrowhead's stock was trading at $60.68. Over the past year the shares have delivered a 257% return, and the company has demonstrated strong recent momentum with a 119% gain over the prior six months, according to InvestingPro analysis.
InvestingPro's evaluation also notes that ARWR appears overvalued relative to its Fair Value. The platform highlighted momentum metrics as one of more than 14 ProTips available to subscribers and pointed to additional Pro Research available for ARWR and other U.S. equities.
The insider sale coincides with Arrowhead's reported financial performance for the first quarter of fiscal year 2026. The company posted earnings per share of $0.22, exceeding the consensus expectation of $0.12 - an 83.33% positive surprise. Revenue for the quarter was $264 million, above the $227.61 million analysts had anticipated.
Despite the upside in top- and bottom-line results, investors reacted to concerns about forward guidance, and the stock traded lower in aftermarket sessions following the earnings release.
Goldman Sachs has retained a Neutral rating on Arrowhead and set a price target of $85.00. The investment bank underscored the company’s recent shift to a commercial-stage profile after the approval of Redemplo for FCS.
Looking toward 2026, Goldman Sachs identified potential catalysts that could influence investor attention, notably the Phase 3 plozasiran SHASTA3/4 trial, with results expected in the third quarter of that year. These upcoming milestones are part of the evolving focus from near-term commercial progress to the company’s clinical pipeline.
Taken together, the Form 4 disclosure and corporate results place insider activity and company fundamentals in the spotlight as Arrowhead transitions its business model and markets assess valuation and future growth drivers.